Kisspeptin dosage: research infusions, not a home-injection protocol

People searching for a kisspeptin “dose” are usually looking for a number to draw into a syringe. That number does not exist in any form a regulator or a careful clinician would endorse. Kisspeptin is a real human reproductive hormone, and it has been given to people — but only inside controlled academic studies, at doses designed by endocrinologists to probe the hormonal axis for a few hours under observation. For what the molecule actually is and what that research found, start with the kisspeptin evidence monograph. This page is narrower: it is about why the research doses are not a protocol you can copy.

How kisspeptin is actually dosed in studies: by infusion, not by syringe

The defining feature of the human kisspeptin literature is the route. In the studies that established its effects, kisspeptin was given intravenously — as a continuous infusion or a controlled bolus — in healthy volunteers, with blood drawn repeatedly to track luteinizing hormone (LH).^[2] The work extending this to men with type 2 diabetes and mild hypogonadism used the same controlled-administration approach to see whether the testosterone axis could be re-engaged.^[3] This matters because the marketed product implies subcutaneous self-injection of a reconstituted powder, a route and setting that none of these foundational studies used.

The doses are weight-based, and that is the point

Research kisspeptin doses are not stated as “X milligrams.” They are scaled to body weight — expressed in picomoles or nanomoles per kilogram per minute for an infusion, or per kilogram for a bolus — precisely so the investigators can deliver a known physiological stimulus and watch the response.^[2] The brain-imaging work pairing kisspeptin with functional MRI likewise used defined infused doses in a scanner, not a fixed amount someone measured at home.^[4] A weight-based infusion rate cannot be meaningfully converted into “units on an insulin syringe” from a vial of unknown concentration; the format itself resists the at-home translation the market wants to make.

Different kisspeptin, different studies, different doses

There is no single “kisspeptin dose” even within the research, because there is more than one molecule and more than one purpose. Much of the male-axis and brain work used kisspeptin-10, the short ten-amino-acid fragment, by infusion.^[2][4] A separate body of fertility research used kisspeptin-54, the longer full-length peptide, as a single bolus to trigger egg maturation in women undergoing IVF — a one-time, tightly supervised use with its own dose-ranging.^[5] A 2022 randomized trial in women with hypoactive sexual desire disorder again used a defined administered dose in a controlled setting.^[6] These are different peptides at different doses for different questions. None of them maps onto a generic “kisspeptin” vial sold as a daily libido or testosterone aid.

Why these doses are research-setting-only

A research dose answers a single, time-limited question — does this hormone move LH, testosterone, or a brain circuit over the next few hours? — with continuous monitoring and the ability to stop. It is not designed to be safe or effective when repeated for weeks by a person at home. The reproductive axis is also governed by feedback and is prone to desensitization with sustained stimulation, which is one reason a clean acute signal in an infusion study does not establish that a repeated self-injected dose would keep working — a pattern we discuss for the growth-hormone axis in our read on ipamorelin & CJC-1295. A leading review of the field frames kisspeptin’s clinical uses as still under investigation, not as settled therapy with a known dose.^[7]

The gap to the “kisspeptin-10” sold online

The product marketed to consumers as “kisspeptin-10” collapses every one of these distinctions. It implies a fixed, self-injected, repeated dose where the research used a weight-based, clinician-delivered, single-session infusion. It borrows the credibility of the genetics — loss-of-function mutations in the kisspeptin receptor cause failure to enter puberty, which is genuine, consensus endocrinology^[1] — and attaches it to a vial that has no validated dose behind it. There is no approved kisspeptin drug for low testosterone or libido, no established self-administration dose, route, or schedule, and no long-term safety record for repeated home injection. The milligrams printed on an unregulated label are also unverified, so even a number copied from a paper would not reliably be the number in the vial.

The honest bottom line

If you reduce kisspeptin dosing to what the evidence supports: it has been administered to people only as a clinician-delivered, weight-based intravenous infusion or supervised bolus, in research designed to probe the reproductive axis and the brain for a few hours under monitoring.^[2][4]Those doses are real, but they are research tools, not a self-injection regimen — and the marketed “kisspeptin-10” vial has no validated dose, route, schedule, or safety record behind it.^[7] The appropriate posture is to respect the science and treat the product as unproven. For the underlying biology and the human findings, see the kisspeptin evidence monograph.